Intense sport practices and cardiac biomarkers

[en] Biomarkers are well established for the diagnosis of myocardial infarction, heart failure and cardiac fibrosis. Different papers on cardiac biomarker evolution during exercise have been published in the literature and generally show mild to moderate elevations. However, the mechanism responsible for these elevations, reflecting physiological or even pathophysiological changes, still has to be clearly elucidated. There are also indications of higher cardiac risk in poorly trained athletes than in well-trained athletes. Whether regular repetition of intensive exercise might lead, in the longer term, to fibrosis and heart failure remains to be determined. In this review, we summarized the main research about the effects of intense exercise (in particular, running) on cardiac biomarkers (including troponins, natriuretic peptides, etc.). We found that cardiac fibrosis biomarkers seemed to be the most informative regarding the biological impact of intense physical activity.

Disciplines :

Orthopedics, rehabilitation & sports medicine

Author, co-author :

LE GOFF, Caroline ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Laboratoire techniques séparatives et stress oxydant

Farre Segura, Jordi ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale

Dufour, Patrice ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Pool assistant - biologie clinique

KAUX, Jean-François ; Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Service de médecine de l'appareil locomoteur

CAVALIER, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Service de chimie clinique

Language :

English

Title :

Intense sport practices and cardiac biomarkers

Publication date :

May 2020

Journal title :

Clinical Biochemistry

ISSN :

0009-9120

eISSN :

1873-2933

Publisher :

Elsevier, Netherlands

Volume :

Pages :

1-8

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 03 March 2020

Statistics

Number of views

242 (32 by ULiège)

Number of downloads

367 (10 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Winterfeld, A., Physical activity guidelines. NCSL Legisbrief. 17 (2009), 1–2.
Nelson, M.E., Rejeski, W.J., Blair, S.N., Duncan, P.W., Judge, J.O., King, A.C., Macera, C.a., Castaneda-Sceppa, C., Physical activity and public health in older adults. Med. Sci. Sport. Exerc. 39 (2007), 1435–1445, 10.1249/mss.0b013e3180616aa2.
Myers, J., Cardiology patient pages. Exercise and cardiovascular health. Circulation 107 (2003), e2–e5.
Paffenbarger, R.S., Hyde, R., Wing, A.L., Hsieh, C., Physical activity, all-cause mortality, and longevity of college alumni. N. Engl. J. Med. 314 (1986), 605–613, 10.1056/NEJM198603063141003.
Faviou, E., Zachari, A., Nounopoulos, C., Agrafiotis, E., Vourli, G., Dionyssiou-Asteriou, A., Elevation of serum N-terminal pro-brain natriuretic peptide after exercise is an index of myocardial damage or a cytoprotective reflection?. J. Sports Med. Phys. Fitness 48 (2008), 90–96.
Chandra, N., Bastiaenen, R., Papadakis, M., Sharma, S., Sudden cardiac death in young athletes: practical challenges and diagnostic dilemmas. J. Am. Coll. Cardiol. 61 (2013), 1027–1040, 10.1016/j.jacc.2012.08.1032.
Sweeting, J., Semsarian, C., Sudden cardiac death in athletes. Hear Lung Circ., 27, 2018, 10.1016/j.hlc.2018.03.026.
Harmon, K.G., Drezner, J.A., Wilson, M.G., Sharma, S., Incidence of sudden cardiac death in athletes: a state-of-the-art review. Br. J. Sports Med. 48 (2014), 1185–1192, 10.1136/bjsports-2014-093872.
Donnellan, E., Phelan, D., Biomarkers of cardiac stress and injury in athletes: what do they mean?. Curr. Heart Fail. Rep. 15 (2018), 116–122, 10.1007/s11897-018-0385-9.
Maessen, M.F.H., Hopman, M.T.E., Verbeek, A.L.M., Eijsvogels, T.M.H., Dose of jogging: mortality versus longevity. J. Am. Coll. Cardiol. 65 (2015), 2672–2673, 10.1016/j.jacc.2015.02.080.
Stevens, S.M., Reinier, K., Chugh, S.S., Increased left ventricular mass as a predictor of sudden cardiac death: is it time to put it to the test?. Circ. Arrhythm. Electrophysiol. 6 (2013), 212–217, 10.1161/CIRCEP.112.974931.
Aengevaeren, V.L., Van Kimmenade, R.R.J., Hopman, M.T.E., VAN Royen, N., Snider, J.V., Januzzi, J.L., George, K.P., Eijsvogels, T.M.H., Exercise-induced changes in Soluble ST2 concentrations in marathon runners. Med. Sci. Sport. Exerc., 1, 2018, 10.1249/MSS.0000000000001806.
Schnohr, P., O'Keefe, J.H., Marott, J.L., Lange, P., Jensen, G.B., Dose of jogging and long-term mortality: the Copenhagen City heart study. J. Am. Coll. Cardiol. 65 (2015), 411–419, 10.1016/j.jacc.2014.11.023.
Nikolaidis, P., Knechtle, B., Age of peak performance in 50-km ultramarathoners – is it older than in marathoners?. Open Access J. Sport. Med. 9 (2018), 37–45, 10.2147/oajsm.s154816.
Knechtle, B., Nikolaidis, P.T., Physiology and pathophysiology in ultra-marathon running. Front. Physiol., 9, 2018, 10.3389/fphys.2018.00634.
Cummins, P., Young, A., Auckland, M.L., Michie, C.A., Stone, P.C.W., Shepstone, B.J., Comparison of serum cardiac specific troponin-I with creatine kinase, creatine kinase-MB isoenzyme, tropomyosin, myoglobin and C-reactive protein release in marathon runners: cardiac or skeletal muscle trauma?. Eur. J. Clin. Invest. 17 (1987), 317–324, 10.1111/j.1365-2362.1987.tb02194.x.
Gresslien, T., Agewall, S., Troponin and exercise. Int. J. Cardiol. 221 (2016), 609–621, 10.1016/j.ijcard.2016.06.243.
Christensen, D.L., Espino, D., Infante-Ramírez, R., Cervantes-Borunda, M.S., Hernández-Torres, R.P., Rivera-Cisneros, A.E., Castillo, D., Westgate, K., Terzic, D., Brage, S., Hassager, C., Goetze, J.P., Kjaergaard, J., Transient cardiac dysfunction but elevated cardiac and kidney biomarkers 24 h following an ultra-distance running event in Mexican Tarahumara. Extrem. Physiol. Med. 6 (2017), 1–10, 10.1186/s13728-017-0057-5.
Goette, A., Bukowska, A., Dobrev, D., Pfeiffenberger, J., Morawietz, H., Strugala, D., Wiswedel, I., Röhl, F.W., Wolke, C., Bergmann, S., Bramlage, P., Ravens, U., Lendeckel, U., Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur. Heart J. 30 (2009), 1411–1420, 10.1093/eurheartj/ehp046.
Shave, R., Baggish, A., George, K., Wood, M., Scharhag, J., Whyte, G., Gaze, D., Thompson, P.D., Exercise-induced cardiac troponin elevation. J. Am. Coll. Cardiol. 56 (2010), 169–176, 10.1016/j.jacc.2010.03.037.
McNeil, P.L., Khakee, R., Disruptions of muscle fiber plasma membranes. Role in exercise-induced damage. Am. J. Pathol. 140 (1992), 1097–1109.
Hultman, E., Sahlin, K., Acid-base balance during exercise. Exerc. Sport Sci. Rev. 8 (1980), 41–128.
Mair, J., Lindahl, B., Hammarsten, O., Müller, C., Giannitsis, E., Huber, K., Möckel, M., Plebani, M., Thygesen, K., Jaffe, A.S., How is cardiac troponin released from injured myocardium?. Eur. Hear. J. Acute Cardiovasc. Care 7 (2018), 553–560, 10.1177/2048872617748553.
Hammarsten, O., Mair, J., Möckel, M., Lindahl, B., Jaffe, A.S., Possible mechanisms behind cardiac troponin elevations. Biomarkers 23 (2018), 725–734, 10.1080/1354750X.2018.1490969.
van Wijk, X.M.R., Claassen, S., Enea, N.S., Li, P., Yang, S., Brouwer, M.A., Cramer, G.E., Zuk, R., Lynch, K.L., Wu, A.H.B., Cardiac troponin I is present in plasma of type 1 myocardial infarction patients and patients with troponin I elevations due to other etiologies as complex with little free I. Clin. Biochem. 73 (2019), 35–43, 10.1016/j.clinbiochem.2019.06.012.
Danielsson, T., Carlsson, J., Schreyer, H., Ahnesjo, J., Ten Siethoff, L., Ragnarsson, T., Tugetam, Å., Bergman, P., Blood biomarkers in male and female participants after an Ironman-distance triathlon. PLoS One 12 (2017), 1–9, 10.1371/journal.pone.0179324.
Eijsvogels, T., George, K., Shave, R., Gaze, D., Levine, B.D., Hopman, M.T.E., Thijssen, D.H.J., Effect of prolonged walking on cardiac troponin levels. AJC 105 (2010), 267–272, 10.1016/j.amjcard.2009.08.679.
Shave, R., Baggish, A., George, K., Wood, M., Scharhag, J., Whyte, G., Gaze, D., Thompson, P.D., Exercise-induced cardiac troponin elevation: Evidence, mechanisms, and implications. J. Am. Coll. Cardiol. 56 (2010), 169–176, 10.1016/j.jacc.2010.03.037.
Shave, R.E., Whyte, G.P., George, K., Gaze, D.C., Collinson, P.O., Prolonged exercise should be considered alongside typical symptoms of acute myocardial infarction when evaluating increases in cardiac troponin T. Heart 91 (2005), 1219–1220, 10.1136/hrt.2004.046052.
Wallace, T.W., Abdullah, S.M., Drazner, M.H., Das, S.R., Khera, A., McGuire, D.K., Wians, F., Sabatine, M.S., Morrow, D.A., De Lemos, J.A., Prevalence and determinants of troponin T elevation in the general population. Circulation 113 (2006), 1958–1965, 10.1161/CIRCULATIONAHA.105.609974.
Jassal, D.S., Moffat, D., Krahn, J., Ahmadie, R., Fang, T., Eschun, G., Sharma, S., Cardiac injury markers in non-elite marathon runners. Int. J. Sports Med. 30 (2009), 75–79, 10.1055/s-0028-1104572.
Middleton, N., George, K., Whyte, G., Gaze, D., Collinson, P., Shave, R., Cardiac troponin T release is stimulated by endurance exercise in healthy humans. J. Am. Coll. Cardiol. 52 (2008), 1813–1814, 10.1016/j.jacc.2008.03.069.
Fu, F., Nie, J., Tong, T.K., Serum cardiac troponin T in adolescent runners: effects of exercise intensity and duration. Int. J. Sports Med. 30 (2009), 168–172, 10.1055/s-0028-1104586.
Urhausen, A., Scharhag, J., Herrmann, M., Kindermann, W., Clinical significance of increased cardiac troponins T and I in participants of ultra-endurance events. Am. J. Cardiol. 94 (2004), 696–698, 10.1016/j.amjcard.2004.05.050.
Chen, Y., Serfass, R.C., Mackey-Bojack, S.M., Kelly, K.L., Titus, J.L., Apple, F.S., Cardiac troponin T alterations in myocardium and serum of rats after stressful, prolonged intense exercise. J. Appl. Physiol. 88 (2017), 1749–1755, 10.1152/jappl.2000.88.5.1749.
Aengevaeren, V.L., Hopman, M.T.E., Thompson, P.D., Bakker, E.A., George, K.P., Thijssen, D.H.J., Eijsvogels, T.M.H., Exercise-induced cardiac troponin I increase and incident mortality and cardiovascular events. Circulation 140 (2019), 804–814, 10.1161/CIRCULATIONAHA.119.041627.
Omland, T., Aakre, K.M., Cardiac troponin increase after endurance exercise. Circulation 140 (2019), 815–818, 10.1161/CIRCULATIONAHA.119.042131.
Clerico, A., Recchia, F.A., Passino, C., Emdin, M., Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am. J. Physiol. Circ. Physiol. 290 (2005), H17–H29, 10.1152/ajpheart.00684.2005.
Wiese, S., Breyer, T., Dragu, A., Wakili, R., Burkard, T., Schmidt-Schweda, S., Füchtbauer, E.-M., Dohrmann, U., Beyersdorf, F., Radicke, D., Holubarsch, C.J.F., Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium. Circulation 102 (2012), 3074–3079, 10.1161/01.cir.102.25.3074.
Dixon, E.M., Kamath, M.V., McCartney, N., Fallen, E.L., Neural regulation of heart rate variability in endurance athletes and sedentary controls. Cardiovasc. Res. 26 (1992), 713–719, 10.1093/cvr/26.7.713.
Le Goff, C., Laurent, T., Kaux, J.-F., Chapelle, J.-P., Intense physical exercise related to the emergent generation of cardio-vascular risk markers: a review. Biol. Sport. 29 (2012), 11–16, 10.5604/20831862.979290.
Le Goff, C., Kaux, J.-F., Goffaux, S.B., Cavalier, E., Cardiac biomarkers and cycling race. J. Sport. Sci. Med., 14, 2015.
Huang, Y.T., Tseng, Y.T., Chu, T.W., Chen, J., Lai, M.Y., Tang, W.R., Shiao, C.C., Corrigendum: N-terminal pro b-type natriuretic peptide (NT-pro-BNP)-based score can predict in-hospital mortality in patients with heart failure. Sci. Rep., 7, 2017, 46866, 10.1038/srep46866.
de Lemos, J.A., Morrow, D.A., Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. Rev. Cardiovasc. Med. 4:Suppl. 4 (2003), S37–S46.
Salvagno, G.L., Schena, F., Gelati, M., Danese, E., Cervellin, G., Guidi, G.C., Lippi, G., The concentration of high-sensitivity troponin I, galectin-3 and NT-proBNP substantially increase after a 60-km ultramarathon. Clin. Chem. Lab. Med. 52 (2014), 267–272, 10.1515/cclm-2013-0601.
Siegel, A.J., Januzzi, J., Sluss, P., Lee-Lewandrowski, E., Wood, M., Shirey, T., Lewandrowski, K.B., Cardiac biomarkers, electrolytes, and other analytes in collapsed marathon runners. Am. J. Clin. Pathol. 129 (2008), 948–951, 10.1309/4L0M60MGAQBCHMV7.
Neumayr, G., Pfister, R., Mitterbauer, G., Eibl, G., Hoertnagl, H., Effect of competitive marathon cycling on plasma N-terminal pro-brain natriuretic peptide and cardiac troponin T in healthy recreational cyclists. Am. J. Cardiol. 96 (2005), 732–735, 10.1016/j.amjcard.2005.04.054.
Dorrian, C.A., Toole, B.J., Alvarez-Madrazo, S., Kelly, A., Connell, J.M., Wallace, A.M., A screening procedure for primary aldosteronism based on the Diasorin Laision automated chemilumuniscent immunoassay for direct renin. Ann. Clin. Biochem. 47 (2010), 195–200.
Scharhag, J., Herrmann, M., Urhausen, A., Haschke, M., Herrmann, W., Kindermann, W., Independent elevations of N-terminal pro-brain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise. Am. Heart J. 150 (2005), 1128–1134, 10.1016/j.ahj.2005.01.051.
Hamasaki, H., The effects of exercise on natriuretic peptides in individuals without heart failure. Sports, 4, 2016, 32, 10.3390/sports4020032.
Rifai, N., Douglas, P.S., O'Toole, M., Rimm, E., Ginsburg, G.S., Cardiac troponin T and I, electrocardiographic wall motion analyses, and ejection fractions in athletes participating in the Hawaii Ironman Triathlon. Am. J. Cardiol. 83 (1999), 1085–1089, 10.1016/S0002-9149(99)00020-X.
Ohba, H., Takada, H., Musha, H., Nagashima, J., Mori, N., Awaya, T., Omiya, K., Murayama, M., Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men. Am. Heart J. 141 (2001), 751–758, 10.1067/mhj.2001.114371.
D'Souza, S.P., Yellon, D.M., Martin, C., Schulz, R., Heusch, G., Onody, A., Ferdinandy, P., Baxter, G.F., B-type natriuretic peptide limits infarct size in rat isolated hearts via K ATP channel opening. Am. J. Physiol. Circ. Physiol. 284 (2015), H1592–H1600, 10.1152/ajpheart.00902.2002.
Scharhag, J., Urhausen, A., Schneider, G., Herrmann, M., Schumacher, K., Haschke, M., Krieg, A., Meyer, T., Herrmann, W., Kindermann, W., Reproducibility and clinical significance of exercise-induced increases in cardiac troponins and N-terminal pro brain natriuretic peptide in endurance athletes. Eur. J. Cardiovasc. Prev. Rehabil. 13 (2006), 388–397, 10.1097/01.hjr.0000219117.33038.90.
Aakre, K.M., Kleiven, Ø., Skadberg, Ø., Bjørkavoll-Bergseth, M.F., Melberg, T., Strand, H., Hagve, T.A., Ørn, S., The copeptin response after physical activity is not associated with cardiac biomarkers or asymptomatic coronary artery disease: the North Sea Race Endurance Exercise Study (NEEDED). Clin. Biochem. 52:2018 (2013), 8–12, 10.1016/j.clinbiochem.2017.10.007.
Lippi, G., Schena, F., Salvagno, G.L., Sanchis-Gomar, F., Guidi, G.C., Serum Copeptin and Midregion Proadrenomedullin (MR-proADM) after an Ultramarathon. J. Clin. Lab. Anal. 29 (2015), 15–20, 10.1002/jcla.21720.
Burge, J., Knechtle, B., Gnadinger, P., Rüst, C.A., Rosemann, T., Maintained serum sodium in male ultra-marathoners – the role of fluid intake, vasopressin and aldosterone in fluid and electrolyte regulation. Zurich Open Repos. Arch. 43 (2011), 646–652.
Hew-Butler, T., Hoffman, M.D., Stuempfle, K.J., Rogers, I.R., Morgenthaler, N.G., Verbalis, J.G., Changes in copeptin and bioactive vasopressin in runners with and without hyponatremia. Clin. J. Sport Med. 21 (2011), 211–217, 10.1097/JSM.0b013e31821a62c2.
La Gerche, A., Claessen, G., Dymarkowski, S., Voigt, J.-U., De Buck, F., Vanhees, L., Droogne, W., Van Cleemput, J., Claus, P., Heidbuchel, H., Exercise-induced right ventricular dysfunction is associated with ventricular arrhythmias in endurance athletes. Eur. Heart J. 36 (2015), 1998–2010, 10.1093/eurheartj/ehv202.
Meijers, W.C., van der Velde, A.R., de Boer, R.A., ST2 and galectin-3: ready for prime time?. Ejifcc 27 (2016), 238–252.
Wu, A.H.B., Wians, F., Jaffe, A., Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am. Heart J. 165 (2013), 995–999, 10.1016/j.ahj.2013.02.029.
Gruson, D., Ko, G., Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?. Clin. Biochem. 45 (2012), 719–726, 10.1016/j.clinbiochem.2012.04.009.
Dumic, J., Dabelic, S., Flögel, M., Galectin-3: an open-ended story. Biochim. Biophys. Acta 1760 (2006), 616–635, 10.1016/j.bbagen.2005.12.020.
de Boer, R.A., van Veldhuisen, D.J., Gansevoort, R.T., Muller Kobold, A.C., van Gilst, W.H., Hillege, H.L., Bakker, S.J.L., van der Harst, P., The fibrosis marker galectin-3 and outcome in the general population. J. Intern. Med. 272 (2012), 55–64, 10.1111/j.1365-2796.2011.02476.x.
Hrynchyshyn, N., Jourdain, P., Desnos, M., Diebold, B., Funck, F., Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch. Cardiovasc. Dis. 106 (2013), 541–546, 10.1016/j.acvd.2013.06.054.
Gupta, A., Ghimire, G., Hage, F.G., Guidelines in review: 2013 ACCF/AHA guideline for the management of heart failure. J. Nucl. Cardiol. 21:2014 (2013), 397–399, 10.1007/s12350-013-9832-x.
Mccullough, P.A., Olobatoke, A., Vanhecke, T.E., Galectin-3: a novel blood test for the evaluation and heart failure. Rev. Cardiovasc. Med. 12 (2011), 200–210, 10.3909/ricm0624.
Trivax, J.E., McCullough, P.A., Phidippides cardiomyopathy: a review and case illustration. Clin. Cardiol. 35 (2012), 69–73, 10.1002/clc.20994.
Hättasch, R., Spethmann, S., de Boer, R.A., Ruifrok, W.P.T., Schattke, S., Wagner, M., Schroeckh, S., Durmus, T., Schimke, I., Sanad, W., Baumann, G., Borges, A.C., Knebel, F., Galectin-3 increase in endurance athletes. Eur. J. Prev. Cardiol. 21 (2014), 1192–1199, 10.1177/2047487313492069.
Le Goff, C., Kaux, J.F., Segura, J.F., Stojkovic, V., Ancion, A., Seidel, L., Lancellotti, P., Cavalier, E., Evolution of the slopes of ST2 and galectin-3 during marathon and ultratrail running compared to a control group. Clin. Chem. Lab. Med., 2019, 10.1515/cclm-2019-0555.
Le Goff, C., Lennartz, L., Vranken, L., Kaux, J.-F., Cavalier, E., Comparison of cardiac biomarker dynamics in marathon, semi-marathon and untrained runners: what is the impact on results interpretation?. J. Lab. Precis. Med., 4, 2019, 10.21037/jlpm.2019.01.04.
Lippi, G., Schena, F., Salvagno, G.L., Aloe, R., Banfi, G., Guidi, G.C., Foot-strike haemolysis after a 60-km ultramarathon. Blood Transfus. 10 (2012), 377–383, 10.2450/2012.0167-11.
Miñana, G., Núñez, J., Bayés-Genís, A., Revuelta-López, E., Ríos-Navarro, C., Núñez, E., Chorro, F.J., López-Lereu, M.P., Monmeneu, J.V., Lupón, J., Bodí, V., ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: a cardiac magnetic resonance study. Int. J. Cardiol. 270 (2018), 336–342, 10.1016/j.ijcard.2018.06.073.
Bayes-Genis, A., Zhang, Y., Ky, B., ST2 and patient prognosis in chronic heart failure. Am. J. Cardiol. 115 (2015), 64B–69B, 10.1016/j.amjcard.2015.01.043.
Peñafiel, J., Lupón, J., Zamora, E., Urrutia, A., Vila, J., de Antonio, M., Barallat, J., Galán, A., Bayes-Genis, A., Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification. J. Am. Coll. Cardiol. 63 (2013), 158–166, 10.1016/j.jacc.2013.07.087.
Benjamin Dieplinger, T.M., Soluble ST2 in heart failure. Heart Fail. Clin. 14 (2018), 41–48, 10.1016/j.hfc.2017.08.005.
Dieplinger, B., Egger, M., Haltmayer, M., Kleber, M.E., Scharnagl, H., Silbernagel, G., de Boer, R.A., Maerz, W., Mueller, T., Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin. Chem. 60 (2014), 530–540, 10.1373/clinchem.2013.209858.
Wang, T.J., Wollert, K.C., Larson, M.G., Coglianese, E., McCabe, E.L., Cheng, S., Ho, J.E., Fradley, M.G., Ghorbani, A., Xanthakis, V., Kempf, T., Benjamin, E.J., Levy, D., Vasan, R.S., Januzzi, J.L., Prognostic utility of novel biomarkers of cardiovascular stress. Circulation 126 (2012), 1596–1604, 10.1161/CIRCULATIONAHA.112.129437.
van de Schoor, F.R., Aengevaeren, V.L., Hopman, M.T.E., Oxborough, D.L., George, K.P., Thompson, P.D., Eijsvogels, T.M.H., Myocardial fibrosis in athletes. Mayo Clin. Proc. 91 (2016), 1617–1631, 10.1016/j.mayocp.2016.07.012.
Mueller, T., Dieplinger, B., Soluble ST2 and galectin-3: what we know and don't know analytically. Ejifcc 27 (2016), 224–237.
Cavus, U., Coskun, F., Yavuz, B., Ciftci, O., Sahiner, L., Aksoy, H., Deniz, A., Ozakin, E., Aytemir, K., Tokgozoglu, L., Kabakci, G., Heart-type, fatty-acid binding protein can be a diagnostic marker in acute coronary syndromes. J. Natl. Med. Assoc. 98 (2006), 1067–1070.
Da Molin, S., Cappellini, F., Falbo, R., Signorini, S., Brambilla, P., Verification of an immunoturbidimetric assay for heart-type fatty acid-binding protein (H-FABP) on a clinical chemistry platform and establishment of the upper reference limit. Clin. Biochem. 47 (2014), 247–249, 10.1016/j.clinbiochem.2014.07.011.
Nakata, T., Hashimoto, A., Hase, M., Tsuchihashi, K., Shimamoto, K., Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology 99 (2003), 96–104, 10.1159/000069726.
Young, J.M., Pickering, J.W., George, P.M., Aldous, S.J., Wallace, J., Frampton, C.M., Troughton, R.W., Richards, M.A., Greenslade, J.H., Cullen, L., Than, M.P., Heart fatty acid binding protein and cardiac troponin: development of an optimal rule-out strategy for acute myocardial infarction. BMC Emerg. Med. 16 (2016), 1–10, 10.1186/s12873-016-0089-y.
Williams, K., George, K., Hulton, A., Godfrey, R., Lahart, I., Wilson, M.G., Charlesworth, S., Warburton, D., Gaze, D., Whyte, G., A unique case series of novel biomarkers of cardiac damage in cyclists completing the 4800 km Race Across America (RAAM). Curr. Med. Chem. 18 (2011), 3446–3451.
Żebrowska, A., Waśkiewicz, Z., Nikolaidis, P.T., Mikołajczyk, R., Kawecki, D., Rosemann, T., Knechtle, B., Acute responses of novel cardiac biomarkers to a 24-h ultra-marathon. J. Clin. Med., 8, 2019, 57, 10.3390/jcm8010057.
Domańska-Senderowska, D., Laguette, M.J.N., Jegier, A., Cieszczyk, P., September, A.V., Brzeziańska-Lasota, E., MicroRNA profile and adaptive response to exercise training: a review. Int. J. Sports Med. 40 (2019), 227–235, 10.1055/a-0824-4813.
Siracusa, J., Koulmann, N., Banzet, S., Circulating myomiRs: a new class of biomarkers to monitor skeletal muscle in physiology and medicine. J. Cachexia. Sarcopenia Muscle 9 (2018), 20–27, 10.1002/jcsm.12227.
Banzet, S., Chennaoui, M., Girard, O., Racinais, S., Drogou, C., Chalabi, H., Koulmann, N., Changes in circulating microRNAs levels with exercise modality. J. Appl. Physiol. 115 (2013), 1237–1244, 10.1152/japplphysiol.00075.2013.